EAU Guidelines on Non–Muscle-Invasive Urothelial Carcinoma of the Bladder, the 2011 Update

Babjuk, Marko; Oosterlinck, Willem; Sylvester, Richard; Kaasinen, Eero; Böhle, Andreas; Palou-Redorta, J.; Rouprêt, Morgan

doi:10.1016/j.eururo.2011.03.017

Cited by 978 publications

(969 citation statements)

References 66 publications

Supporting

Mentioning

900

Contrasting

Unclassified

Order By: Relevance

“…Clinically, bladder cancer can be divided into non-muscle-invasive bladder cancer (NMIBC) and muscle-invasive bladder cancer (MIBC), with different treatments and outcome (4). NMIBC accounts for ~75-85% of all bladder cancers, with relatively higher overall survival rates compared with MIBC (5).…”

Section: Introductionmentioning

confidence: 99%

TRAF6 expression is associated with poorer prognosis and high recurrence in urothelial bladder cancer

Hao

Cui

et al. 2017

Oncology Letters

View full text Add to dashboard Cite

Abstract. The aim of the present study was to investigate the clinical significance of TNF receptor-associated factor 6 (TRAF6) expression in urothelial bladder cancer. TRAF6 expression was detected by immunohistochemistry in 126 samples of patients with urothelial bladder cancer. The association between clinicopathological factors and TRAF6 expression was analyzed by χ 2 test. The association between TRAF6 expression, overall survival rate and the recurrence-free survival rate was evaluated in univariate analysis with Kaplan-Meier test and in multivariate analysis with Cox-regression model. In the cohort tested, the rate of high TRAF6 expression was 61.9% (78/126). TRAF6 expression was demonstrated to be significantly associated with positive metastasis (P=0.001) with χ 2 test. Furthermore, TRAF6 expression was demonstrated to be associated with overall survival rate (P=0.016) and recurrence-free survival rate (P=0.016). With Cox-regression model, it was indicate that TRAF6 high expression was an independent predictive factor of poor prognosis (P=0.037) and high recurrence (P=0.011). High TRAF6 expression may predict unfavorable prognosis and high recurrence in urothelial bladder cancer, indicating that TRAF6 may be a potential and promising therapeutic target in urothelial bladder cancer.

show abstract

Section: Introductionmentioning

confidence: 99%

TRAF6 expression is associated with poorer prognosis and high recurrence in urothelial bladder cancer

Hao

Cui

et al. 2017

Oncology Letters

View full text Add to dashboard Cite

show abstract

“…NMIBT is treated by transurethral resection of the bladder (TURB) and with intravesical chemotherapy. Furthermore, all patients undergo follow-up visits [2]. MIBT requires radical cystectomy, chemotherapy, radiation therapy or a combination [3] depending of the stage and the condition of the patient.…”

Section: Introductionmentioning

confidence: 99%

MRI of the Bladder in Patients Suspected of Bladder Tumors

Gandrup¹,

Nordling²,

Thomsen³

2014

OJRad

View full text Add to dashboard Cite

Objective: To prospectively evaluate the use of MRI for the detecting of bladder tumors and the Tstage using T2W, T1W and diffusion-weighted images (DWI). Material and methods: Twenty-eight consecutive patients (21 men, 7 women; age range, 20 -82 years; mean age, 62.8 years) suspected of bladder tumors underwent MRI, flexible cystoscopy and transurethral resection (TURB). The presence of bladder tumor was confirmed by histopathology in 21 patients; 18 patients had pTa, one pT1 and two pT2. The images were reviewed by two uroradiologists. They assigned the presence of a bladder tumor and whether the tumor was non-muscle invasive (Ta and T1) or muscleinvasive (T2, T3 or T4). Results: Compared to the histopathological results, the accuracy for identifying a bladder tumor was 60.7% and 53.7% for reviewer A and B, respectively. The sensitivity and specificity were 66.7%/61.9% and 57.1%/42.9%. Positive predictive values were 82.6%/ 76.5%. The overall staging was correct in 47.6%/52.5%, but improved on stage-by-stage up to 50%/66.7%. The agreement between the reviewers was moderate in the detecting, staging and location of the tumor (Kappa = 0.47 -0.57). Conclusion: A simple MRI using no contrast media, but DWI, cannot replace flexible cystoscopy in the detection of new or recurrent bladder tumors.

show abstract

“…Surgical technologies are improving, however when patients undergo radical cystectomy and systemic chemoradiotherapy, distant metastasis occurs in ~50% of the tumors within two years and the five-year mortality rate is ≤60% (6). Given the high recurrence and progressive rate of BUC, patients often require a lengthy and expensive follow-up (3). Thus, the early detection of superficial tumors that exhibit an infiltrating tendency, and invasive tumors with metastatic potential, is important for the development of therapeutic treatment strategies and establishing an accurate prognosis (7,8).…”

Section: Introductionmentioning

confidence: 99%

“…In the United States, bladder cancer is the third most common malignant tumor in males and the tenth in females (2). Bladder urothelial carcinoma accounts for ~90% of all cases of bladder cancer, 75-85% of which is classed as non-muscle invasive bladder urothelial cancer (NMIBUC), while the remainder is muscle invasive BUC (MIBUC) (3). Transurethral resection of bladder cancer combined with postoperative chemotherapy is the predominant therapeutic method to treat NMIBUC, which has a five-year survival rate of 85-90% (4,5).…”

Section: Introductionmentioning

confidence: 99%

Effect of quantum dots on the biological behavior of the EJ human bladder urothelial carcinoma cell line

Yuan

Zhang

et al. 2015

Molecular Medicine Reports

View full text Add to dashboard Cite

Abstract. Quantum dots (QDs) are a type of fluorescent label with applications in biological molecules, cells and in vivo imaging. The current study investigated the effect of QDs on the toxicity, proliferation, migration and invasion of the EJ human bladder cancer cell line in vitro. The cell counting kit-8 test was used to measure the survival rate of EJ cells following incubation with varying concentrations of QDs. Additionally, the effect of QDs on tumor cell migration and invasion was evaluated using the Transwell chamber assay, and cell proliferation rate was assessed using a hemocytometer. Data from the current study demonstrated no significant differences in survival rate between the experimental and control groups with the conventionally used concentrations (5, 10 and 20 nM) of QD605 (P>0.05). However, with high concentrations of QD605 (40 and 80 nM), significant differences were observed (P<0.001). The survival rate of EJ cells, however, remained at 92.6%. In addition, no significant differences were observed between the EJ cells labeled with transactivator of transcription (TAT)-QD605 and the unlabeled EJ cells with regard to proliferation, migration and invasion (P>0.05). Thus, the results of the current study indicate that QDs exhibit a certain degree of influence on the activity of the EJ bladder cancer cell line at high concentrations. However, at the concentrations that QDs are conventionally used, there was little impact on the survival of the EJ cells. In addition, the proliferation, migration and invasion abilities of the EJ cells were not affected by TAT-QDs. Therefore, the peptide-conjugated QDs have potential to be applied in the imaging and tracking of live cells in vitro and of animals in vivo. Notably, QDs may provide the foundation for a novel, non-invasive imaging strategy for the early diagnosis of tumors.

show abstract

EAU Guidelines on Non–Muscle-Invasive Urothelial Carcinoma of the Bladder, the 2011 Update

Cited by 978 publications

References 66 publications

TRAF6 expression is associated with poorer prognosis and high recurrence in urothelial bladder cancer

TRAF6 expression is associated with poorer prognosis and high recurrence in urothelial bladder cancer

MRI of the Bladder in Patients Suspected of Bladder Tumors

Effect of quantum dots on the biological behavior of the EJ human bladder urothelial carcinoma cell line

Contact Info

Product

Resources

About